Association of microRNA gene polymorphisms with Type 2 diabetes mellitus: A systematic review and meta-analysis

Morteza Gholami1,2, Saeedeh Asgarbeik1, Farideh Razi1, Ensieh Nasli Esfahani1, Marzieh Zoughi1, Aida Vahidi1, Bagher Larijani2, Mahsa Mohammad Amoli1

1Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, 2Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, 3Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

INTRODUCTION

Type 2 diabetes mellitus (T2DM) as a metabolic disorder is caused by insulin resistance and beta-cell dysfunction. The prevalence of diabetes is rapidly growing, especially in middle- and low-income countries. In 2014, 422 million people had diabetes, which means 8.5/100 persons, which may increase to 592 million till 2035. More than 90% of these patients develop type-2 diabetes. In recent years, diabetes leads to approximately 4 million deaths, as direct or indirect cause each year, and it is proclaimed as the seventh cause of death by the World Health Organization. T2DM micro- and macrovascular complications obligate increasing financial and social burden on communities. The world direct annual cost of T2DM is estimated over 800 billion dollars.

How to cite this article: Gholami M, Asgarbeik S, Razi F, Esfahani EN, Zoughi M, Vahidi A, et al. Association of microRNA gene polymorphisms with Type 2 diabetes mellitus: A systematic review and meta-analysis. J Res Med Sci 2020;25:56.
factors including genetic, family history, diet, low physical activity, smoking, high body mass index, and aging are responsible for the increasing prevalence of T2DM.\[^{[3,4]}\] Majority of T2DM patients suffer from obesity. High level of FFA in obese individuals correlates with beta-cell dysfunction and insulin resistance in T2DM.\[^{[5]}\] Both genetics and environmental factors are involved in the development of diabetes mellitus.\[^{[6]}\] In many studies, various candidate genes are proposed which are involved in the development of T2DM such as peroxisome proliferator-activated receptor gamma, glycogen synthase, insulin receptor substrate 1, insulin, potassium voltage-gated channel subfamily J member 1, ATP-binding cassette subfamily C member 8, and solute carrier family 2 member 1.\[^{[7]}\] These genes play roles in diabetes by several mechanisms.

MicroRNAs are small, conserved ncRNA molecules that are involved in most cellular processes through interaction with 3'-UTR region of the genes.\[^{[8]}\] miRNAs are important small noncoding RNAs that regulate RNAs and gene expression in various common diseases such as T2DM.\[^{[9]}\] miRNAs seem to play a role in the development of pancreatic islets and differentiation of insulin-producing cells.\[^{[10]}\] For instance, mir-375 is involved in insulin secretion by interaction with myotrophin gene and development of islets.\[^{[11]}\] The interaction of FoxA2 and Rab27A genes with miR-124a has also been proven influential in the development of islet cells.\[^{[12]}\] On the other hand, polymorphisms in miRNAs may be functionally important by regulation of target genes or transcription of miRNAs.\[^{[13]}\] These polymorphisms may affect the risk, development, progress, or morbidity associated with diabetes, by further effect on miRNA target genes.\[^{[14]}\] There are several studies on the role of miRNA polymorphisms in T2DM, but no systematic review or meta-analysis was performed yet. Only two reviews in 2017 and 2018 have been conducted on this subject. In 2017, Zhuang and Wang studied the polymorphisms related to diabetes mellitus and its complications in miRNA genes or their target sites.\[^{[15]}\] In 2018, Zhang et al. reviewed the miRNA polymorphisms associated with diabetes mellitus and its complications.\[^{[16]}\] However, their studies did not accomplish with all requirements. For instance, they included only few polymorphisms, from Cicciacci et al.,\[^{[17]}\] while this study contains more miRNA polymorphism. Furthermore, some studies were inadequately added in their report including the study by Alipoor et al.\[^{[18]}\] with MAF 0.25 which was designed to investigate the role of miRNA variant on miR-146a expression, or the study by Hara et al.\[^{[19]}\] in Zhang review that was a GWA study and should be excluded in our systematic review.

The aim of the current study was to systematically search all miRNA polymorphism-related documents and further meta-analysis of results for their association with T2DM.

### MATERIALS AND METHODS

**Data sources (electronic and hand-searching)**

The strategy has been developed based on the PRISMA-P 2015 checklist.\[^{[20]}\] Figure 1, the PRISMA 2009 flow diagram,\[^{[21]}\] shows the review process.

We systematically searched literatures in Web of Science, PubMed, Embase, and Scopus databases. Syntax definition was performed by combining Medical Subject Headings (MeSH) and free text. Key search terms were “Diabetes Mellitus, Type 2,” “MicroRNAs,” “Polymorphism, Single Nucleotide,” and their equivalents. We also did a search on key journals and references of relevant review/meta-analysis. The second search was performed after first data collections; the search was based on included polymorphisms to find all relevant documents.

**Types of studies and participants**

Primary documents were screened according to this review strategy. We included case–control, cohort, and cross-sectional studies as three types of observational studies, with data being related to the association between miRNA polymorphisms and T2DM. All other studies were excluded. Studies that their controls were healthy people were included and others were excluded. Studies with insufficient data or with deviation from Hardy–Weinberg equilibrium\[^{[22]}\] were excluded. Insufficient data were resolved by contact with the corresponding author. If we had not received any response after three E-mails, the data were excluded from meta-analysis. Search was performed for documents restricted to publication dates from January 1, 1992, to November 30, 2019, to find the most recent documents which were more reliable. Documents in all languages were included. There was also no restriction about the age, gender, race, or genotyping methods. Documents with diabetes complications such as nephropathy, retinopathy, and other traits were excluded. The quality assessment has been applied by Newcastle–Ottawa Scale method.\[^{[23]}\]

**Data collection**

Data collection was carried out in three steps: first, removing duplications; second, three reviewers (M.Z., S.A., and A.V.) independently checked title/abstract to find included studies and studies with uncertainty. Disagreements and uncertainties were resolved by both consensus strategy and third-person strategies; at the final step, full texts were investigated by three reviewers (M.Z., S.A., and A.V.). Data extraction was performed by two reviewers (M.G. and M.M.A.) for the following data: first author name, country of study, publication year, study design, ethnicity, gender, polymorphisms, miRNAs, and genotyping methods.
Disagreements between reviewers were resolved by previously described strategies.

Statistical analysis
Data analysis was performed using R programming language 3.5.2 (R: A language and environment for statistical computing; R Foundation for Statistical Computing, Vienna, Austria; URL http://www.R-project.org/) and STATA software V.13 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX, USA: StataCorp LP). The associations between included polymorphisms and T2DM were assessed by odds ratio (OR) and confidence interval (95% CI) for OR. The meta-analysis was performed based on allelic, homozygous, heterozygote, dominant, and recessive genetic models. All genetic models were analyzed in both two random and fixed models. Heterogeneity was assessed by the Cochran’s Q test. We used random effects model if Q test was \( P < 0.05 \) and the I\(^2\) statistic was more than 50% in forest plots. For each polymorphism, if sufficient studies were included, subgroup analysis was performed based on ethnicity. To find publication bias in primary studies, we assessed Egger’s and Begg’s tests. The results were depicted by funnel plots. Sensitivity analysis was carried out by leave-one-out method, based on omit studies one by one.

RESULTS

Study selection
Based on our double systematic searching and after removing duplication, 1922 articles were included. The flow diagram and data related to screening are shown in Figure 1. Among 15 included studies (32 polymorphisms), we found two articles for two single-nucleotide polymorphisms (rs3820455 and rs11888095), three studies were included for rs3746444 and rs531564 polymorphisms, and also more than three studies were included for each of the following polymorphisms (rs895819, rs11614913, and rs2910164). These data are summarized in Table 1.

Meta-analysis
When we combined data related to polymorphisms with two included articles, it was observed that C and T alleles of rs3820455 and rs11888095, respectively, may increase the risk of T2DM, but the results were not significant (data are not shown). Furthermore, analysis of three included...
Table 1: Basic characteristics of included studies

| First author | Year | Country | Ethnicity | Study design | Quality score | Gender | Source | Genotyping method | miRNAs | Single-nucleotide polymorphism | Sample size (case/control) |
|--------------|------|---------|-----------|--------------|---------------|--------|--------|------------------|--------|-----------------------------|--------------------------|
| Alipoor et al.[28] | 2016 | Iran | Caucasian | Case/control | 8 | Male/female | PB | PCR-RFLP | miR-146a | rs2910164 | 183/192 |
| Buraczynska et al.[39] | 2014 | Poland | Caucasian | Case/control | 8 | Male/female | PB | PCR-RFLP | miR-196a2 | rs1614913 | 920/834 |
| Ciccacci et al.[24] | 2017 | Italy | Caucasian | Case/control | 7 | Male/female | PB | Sequencing | miR-375 | rs6715345 | 100/75 |
| | | | | | | | | | miR-27a | rs895819 | 148/147 |
| | | | | | | | | | miR-130b | rs861843 | 161/145 |
| | | | | | | | | | miR-124a | rs531564 | 162/178 |
| | | | | | | | | | miR-124a | rs73662598 | 163/178 |
| | | | | | | | | | miR-128a | rs11888095 | 108/85 |
| | | | | | | | | | miR-194a | rs3820455 | 144.92 |
| | | | | | | | | | miR-146a | rs2910164 | 153/181 |
| Ghaedi et al.[40] | 2016 | Iran | Caucasian | Case/control | 8 | Male/female | HB | PCR-RFLP | miR-27a | rs895819 | 204/209 |
| Li et al.[41] | 2015 | China | ESA | Case/control | 7 | Male/female | PB | TaqMan | miR-27a | rs895819 | 738/610 |
| | | | | | | | | | miR-124a | rs531564 | 738/610 |
| | | | | | | | | | miR-128a | rs11888095 | 738/610 |
| | | | | | | | | | miR-194a | rs3820455 | 738/610 |
| | | | | | | | | | miR-146a | rs2910164 | 738/610 |
| Sun et al.[42] | 2018 | China | ESA | Case/control | 6 | Male/female | PB | Sequencing | miR-34a | rs12128240 | 130/117 |
| | | | | | | | | | miR-34a | rs2666433 | 130/117 |
| | | | | | | | | | miR-34a | rs6577555 | 130/117 |
| Wang et al.[37] | 2015 | China | ESA | Case/control | 7 | Male/female | PB | SNPscan Kit | miR-27a | rs895819 | 995/967 |
| | | | | | | | | | miR-124a | rs2910164 | 995/967 |
| | | | | | | | | | miR-128a | rs531564 | 995/967 |
| Zhou et al.[43] | 2013 | China | ESA | Case/control | 7 | Male/female | PB | PCR-RFLP | let-7a-2 | rs1443770 | 104/62 |
| | | | | | | | | | let-7a-2 | rs547008 | 104/62 |
| Chen et al.[44] | 2014 | China | ESA | Case/control | 5 | Male/female | PB | PCR-LDR | miR-149 | rs71428439 | 33/856 |
| | | | | | | | | | miR-146a | rs2910164 | 33/856 |
| | | | | | | | | | miR-128a | rs1134527 | 33/856 |
| | | | | | | | | | miR-196a2 | rs1164913 | 33/856 |
| | | | | | | | | | mir-499 | rs3746444 | 33/856 |
| Huang et al.[45] | 2015 | China | ESA | Case/control | 5 | Male/female | HP | TaqMan | miR-146a | rs2910164 | 46/485 |
| | | | | | | | | | miR-196a2 | rs1164913 | 46/485 |
| Zhi et al.[46] | 2012 | China | ESA | Case/control | 5 | Male/female | HP | PCR-RFLP | miR-196a2 | rs1614913 | 38/252 |
| | | | | | | | | | miR-499 | rs3746444 | 38/252 |
| Huang et al.[47] | 2015 | China | ESA | Case/control | 7 | Male/female | HP | TaqMan | miR-146a | rs2910164 | 45/672 |
| | | | | | | | | | miR-196a2 | rs1164913 | 45/675 |
| Li et al.[48] | 2019 | China | ESA | Case/control | 7 | Male/female | PB | MassArray | miR-135a-2 | rs10459194 | 784/846 |
| | | | | | | | | | let-7d | rs10993081 | 784/846 |
| | | | | | | | | | let-7d | rs7045890 | 784/846 |
| | | | | | | | | | miR-107 | rs2296616 | 784/846 |
| | | | | | | | | | miR-96 | rs2402959 | 784/846 |
| | | | | | | | | | miR-96 | rs695644 | 784/846 |
| | | | | | | | | | miR-29a | rs24168 | 784/846 |
| | | | | | | | | | miR-23a | rs3745453 | 784/846 |
| | | | | | | | | | miR-126 | rs4636297 | 784/846 |
| | | | | | | | | | miR-133a-1 | rs8089787 | 784/846 |
| | | | | | | | | | miR-133a-1 | rs9948906 | 784/846 |
| | | | | | | | | | miR-106b | rs999885 | 784/846 |
| Mohsen et al.[49] | 2018 | Iraq | Caucasian | Case/control | 5 | Male/female | PB | PCR-RFLP | miR-499 | rs3746444 | 80/40 |
| Moudi and Zohouri[50] | 2018 | Iran | Caucasian | Case/control | 6 | Male/female | PB | PCR-RFLP | miR-605 | rs2043556 | 300/300 |
articles for rs531564 and rs3746444 polymorphisms showed no significant results (data are not shown).

Seven studies were included for rs2910164. Seven studies with 2193 cases and 3963 controls were included for rs2910164 polymorphism. In overall analysis, the meta-analysis showed no significant association. Subgroup analysis for ethnicity showed that in Caucasians, there was a significant association in homozygote model (OR = 1.78; 95% CI: 1.06–3.00; F = 35%, Q test P = 0.22), heterozygote model (OR = 1.77; 95% CI: 1.03–3.05; F = 0%, Q test P = 0.57), and recessive model (OR = 1.78; 95% CI: 1.07–2.96; F = 4%, Q test P = 0.31). The plots are shown in Figure 2.

Five studies were included in the meta-analysis for rs11614913. Five studies with 1082 cases and 3102 controls were included for rs11614913 polymorphism. The results showed that T allele significantly decreased risk of T2DM in four genetic models: overdominant model (OR = 0.83; 95% CI: 0.70–0.97; F = 32%, Q test P = 0.21), dominant model (OR = 0.73; 95% CI: 0.62–0.88; F = 57%, Q test P = 0.05), homozygote model (OR = 0.76; 95% CI: 0.59–0.98; F = 52%, Q test P = 0.08), and heterozygote model (OR = 0.75; 95% CI: 0.62–0.90; F = 51%, Q test P = 0.09). However, subgroup analysis for rs11614913 in Chinese population showed no significant results [Figure S1].

Four studies with 2085 cases and 1933 controls were included for rs895819 polymorphism. Meta-analysis for rs895819 showed no significant association with the C allele, but subgroup analysis revealed significantly decreased risk of T2DM in Caucasians with recessive model (OR = 0.34; 95% CI: 0.18–0.66; F = 0%, Q test P = 0.32), dominant model (OR = 0.70; 95% CI: 0.52–0.94; F = 0%, Q test P = 0.44, F = 13%), heterozygote model (OR = 0.37; 95% CI: 0.19–0.74; F = 0%, Q test P = 0.43), allelic model (OR = 0.67; 95% CI: 0.52–0.85; F = 0%, Q test P = 0.39). The plots are shown in Figure 3. The results for publication bias and sensitivity analysis are presented in Figures S2 and S3, respectively.

**DISCUSSION**

**Main findings and interpretation**

This study aimed to systematically investigate the role of miRNA gene polymorphisms on the risk of T2DM. For this purpose, we performed an overall meta-analysis and subgroup analysis for eligible studies.

Our results showed that C allele of rs2910164 polymorphism increased the risk of T2DM in subgroup analysis, as the risk effect was stronger in Caucasians. This polymorphism is located on miR-146a gene. The conversion of G to C in rs2910164 causes a mispairing in pre-microRNA structure and maturation process, which leads to decrease of both pre/mature miR-146a.[51] Furthermore, the decreased expression of this miR-146a has been reported in the serum of patients with diabetes compared to the healthy control group.[52] On the other hand, miRNA-mRNA interaction
can play a role in disease-related gene expression or gene regulations. In T2DM, it is shown that this miRNA has interaction with inflammatory genes including TRAF6, NFKB, TNFα, and IL-6, which are involved in the pathogenesis of T2DM. Lower expression of miR-146a is associated with higher expression of inflammatory markers, insulin resistance, poor glycemic control, and the overall progression to diabetes.\[53]\ The reduced level of miR-146a, caused by C allele, may be an important factor for induction of inflammatory mechanism involved in T2DM. These causal relationships may justify the higher frequency of allele C and the role of rs2910164 polymorphism in T2DM patients.

The rs11614913 polymorphism in miR-196a is located on chromosome 17 between HOX genes and also has interaction with HOX genes.\[54,55]\ HOX genes play an important role in the initial development of fetal organs including pancreas.\[56]\ In addition, miR-196a can activate the AKT signaling pathway, which is involved in the development and treatment of type 2 diabetes.\[57,58]\ elucidating the importance of miR-196 in the pathology of diabetes. Converting C to T allele in rs11614913 polymorphism influences the processing of miR-196a2 and its function.\[59]\ Meta-analysis in this study showed that the T allele of this polymorphism has a protective effect on the risk of T2DM, which is similar to the study by Buraczynska et al. on Caucasians.\[39]\ No such association was observed in the subgroup analysis (Chinese studies), and even, it seems that in Chinese population, the T allele was tended to increase the risk of T2DM. The reason for the discrepancy in the total and subgroup analysis may be the result of the larger sample size in Caucasian study. Furthermore, previous studies such as gnomAD-Exomes and 1000 Genomes determined that the frequency of allele T was considerably different between East Asian and other parts of the world and C allele frequency was higher in East Asian population. Therefore, it may affect result for association between T allele and T2DM in this population. However, these results should be interpreted with cautious and nondecisively. Based on the important role of miR-196a and inconclusive results for the role of rs11614913 polymorphism in T2DM, additional observational studies on different ethnic populations seem to be essential.

We did not find a significant relation between rs895819 and T2DM. It may be related to few studies included and also ethnicity differences between groups. Based on subgroup
analysis, we found significant associations in different genetic models, and variant allele seemed to decrease risk of T2DM in Caucasians, which suggests the protective effect for this allele. Most of the previous studies for this polymorphism were related to its role in cancers. Previously, a meta-analysis showed the ethnic effect on the role of this polymorphism in risk of cancers,[68] which may approve the role of ethnic variation for association with this polymorphism. The miR-27a has high expression in high glycemic condition in adipose tissue.[69] Higher level of this miRNA increases expression of pro-inflammatory cytokines and plays positive roles in inflammatory response.[62] The rs895819 in pri-miR-27a may be involved in processing and function of this miRNA.[63] In this study, the association with this polymorphism was merely affirmed in two included studies.

The rs531564 polymorphism in the pri-miRNA influences the expression of miR-124.[64] However, we did not observe any correlation between rs531564 and T2DM, which can be as a result of an insufficient number of studies, small sample size, and various ethnicities.

Strengths and limitations
The strengths of our study are as follows: first, this is the first systematic review and meta-analysis, on the role of miRNA polymorphisms on T2DM, and has been performed without any language limitation. Second, we included four main databases as well as hand-searching. Third, three steps of title/abstract screening, full-text eligibility, and data extraction are done by two researchers independently. The limitations of our study are as follows: one of the main causes of heterogeneity in our study was different ethnic populations. Because of the small number of included studies in some cases, subgroup analysis was done by only two included articles. Furthermore, meta-analysis was performed for some included polymorphisms.

CONCLUSION
In this meta-analysis, we found that minor alleles of polymorphisms in miR-146a (rs2910164) and miR-27a (rs895819) inversely affect T2DM susceptibility, especially in Caucasian population. The minor allele of rs2910164 may increase the risk of T2DM by leading to lower level of miR-146a and consequently higher expression of inflammatory markers involved in T2DM. In contrast, minor allele of rs895819 may decrease the risk of T2DM by leading to higher level of miR-27a increasing the effect of inflammatory genes involved in T2DM.

Financial support and sponsorship
This study was supported by Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences (Grant No. 1397-02-97-2276).

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
2. Seino Y, Nanjo K, Tajima N, Kadukawa T, Kashiwagi A, Eiichi Araki E, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010;1:212-8.
3. World Health Organization. Global Report on Diabetes; 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf?sequence=1.
4. Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W. Diabetes prevalence and socioeconomic status: A population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health 2000;54:173-7.
5. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37 Suppl 1:S81-90.
6. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections to 2035. Diabetes Res Clin Pract 2014;103:137-49.
7. World Health Organization. Fact Sheet on Diabetes; 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes. [Last accessed on 04 Dec 2020].
8. Boden G, Shulman G. Shulman, free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 2002;32:14-23.
9. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 2013;9:513-21.
10. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
11. Farazi TA, Spitzer JI, Morozov P, Tuschi T. miRNAs in human cancer. J Pathol 2011;223:102-15.
12. Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, van Oudenaarden A. MicroRNAs can generate thresholds in target gene expression. Nat Genet 2011;43:854-9.
13. Amores SL, Zamoire PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013;14:475-88.
14. Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol 2011;48:61-9.
15. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharfmann R, et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 2007;282:19575-88.
16. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol 2007;5:e203.
17. Tang X, Tang G, Özcan S. Role of microRNAs in diabetes. Biochim Biophys Acta Gene Regul Mech 2008;1779:697-701.
18. Poy MN, Spranger M, Stoffel M. microRNAs and the regulation of glucose and lipid metabolism. Diabetes Obes Metab 2007;9 Suppl 2:67-73.
19. Gauthier BR, Wollheim CB. MicroRNAs: ’ribo-regulators’ of glucose homeostasis. Nat Med 2006;12:36-8.
20. Poy MN, Eliasson L, Kruetzfeldt J, Kuwajima S, Ma X, Macdonald PE, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;429:226-30.
21. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 2008;389:305-12.
genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 2009;18:1183-7.

60. Chen M, Fang W, Wu X, Bian S, Chen G, Lu L, et al. Distinct effects of rs895819 on risk of different cancers: An update meta-analysis. Oncotarget 2017;8:75336-49.

61. Herrera BM, Lockstone HE, Taylor JM, Ria M, Barrett A, Collins S, et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010;53:1099-109.

62. Xie N, Cui H, Banerjee S, Tan Z, Salomao R, Fu M, et al. miR-27a regulates inflammatory response of macrophages by targeting IL-10. J Immunol 2014;193:327-34.

63. Song B, Yan G, Hao H, Yang B. rs11671784 C/A and rs895819 A/G polymorphisms inversely affect gastric cancer susceptibility and miR-27a expression in a Chinese population. Med Sci Monit 2014;20:2318-26.

64. Moazeni-Roodi A, Hashemi M. Association between miR-124-1 rs531564 polymorphism and risk of cancer: An updated meta-analysis of case-control studies. EXCLI J 2018;17:608-19.
Figure S1: Forest plot related to rs11614913 and risk of Type 2 diabetes mellitus. (a) Overdominant model, (b) dominant model, (c) homozygote model, and (d) heterozygote model.
Figure S2: Funnel plots of publication bias for the relation between polymorphism and risk of Type 2 diabetes mellitus. rs2910164: (a1) dominant model, (b1) homozygote model, (c1) heterozygote model, and (d1) recessive model. rs11614913: (a2) overdominant model, (b2) dominant model, (c2) homozygote model, and (d2) heterozygote model. rs895819: (a3) recessive model, (b3) dominant model, (c3) homozygote model, (d3) heterozygote model, and (e3) allelic model.
Figure S3: Sensitivity forest plots for the relation between polymorphism and risk of Type 2 diabetes mellitus. rs2910164: (a1) dominant model, (b1) homozygote model, (c1) heterozygote model, and (d1) recessive model. rs11614913: (a2) overdominant model, (b2) dominant model, (c2) homozygote model, and (d2) heterozygote model. rs895819: (a3) recessive model, (b3) dominant model, (c3) homozygote model, (d3) heterozygote model, and (e3) allelic model.